Skip to main content

ULTRALIFE CORP

For the period ended Mar 31, 2024. Filed Apr 25, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed Apr 25, 2024

ULBI$15.66+0.2%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Item 1. Consolidated Financial Statements (unaudited)

Consolidated Balance Sheets as of March 31, 2024 and December 31, 20231
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the Three-Month Periods Ended March 31, 2024 and March 31, 20232
Consolidated Statements of Cash Flows for the Three-Month Periods Ended March 31, 2024 and March 31, 20233
Consolidated Statements of Changes in Stockholders’ Equity for the Three-Month Periods Ended March 31, 2024 and March 31, 20234
Notes to Consolidated Financial Statements5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations15
Item 4.Controls and Procedures23
PART II.OTHER INFORMATION
Item 6.Exhibits24
Signatures25

PART I. FINANCIAL INFORMATION

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Thousands except share amounts)

(Unaudited)

March 31, 2024December 31, 2023
ASSETS
Current assets:
Cash$10,099$10,278
Trade accounts receivable, net of allowance for expected credit losses of $300 and $300, respectively35,27831,761
Inventories, net43,82142,215
Prepaid expenses and other current assets5,1045,949
Total current assets94,30290,203
Property, plant and equipment, net20,67021,117
Goodwill37,49937,571
Other intangible assets, net14,86715,107
Deferred income taxes, net9,87310,567
Other noncurrent assets3,3403,711
Total assets$180,551$178,276
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$13,315$11,336
Current portion of long-term debt2,0002,000
Accrued compensation and related benefits2,0133,115
Accrued expenses and other current liabilities6,0487,279
Total current liabilities23,37623,730
Long-term debt23,14023,624
Deferred income taxes1,6751,714
Other noncurrent liabilities3,4153,781
Total liabilities51,60652,849
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued--
Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 20,887,446 shares at March 31, 2024 and 20,783,607 shares at December 31, 2023; outstanding – 16,451,332 shares at March 31, 2024 and 16,347,493 shares at December 31, 20232,0892,078
Capital in excess of par value189,995189,160
Accumulated deficit(37,863)(40,754)
Accumulated other comprehensive loss(3,892)(3,660)
Treasury stock - at cost; 4,436,114 shares at March 31, 2024 and 4,436,114 shares at December 31, 2023(21,492)(21,492)
Total Ultralife Corporation equity128,837125,332
Non-controlling interest10895
Total stockholders’ equity128,945125,427
Total liabilities and stockholders’ equity180,551$178,276

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (In Thousands except per share amounts) (Unaudited)

Three-month period ended
March 31, 2024March 31, 2023
Revenues$41,927$31,916
Cost of products sold30,45724,480
Gross profit11,4707,436
Operating expenses:
Research and development1,7562,032
Selling, general and administrative5,6515,378
Total operating expenses7,4077,410
Operating income4,06326
Other (expense) income:
Interest and financing expense(520)(424)
Miscellaneous income (expense)64(70)
Total other expense(456)(494)
Income (loss) before income taxes3,607(468)
Income tax provision (benefit)703(133)
Net income (loss)2,904(335)
Net income attributable to non-controlling interest(13)(11)
Net income (loss) attributable to Ultralife Corporation2,891(346)
Other comprehensive (loss) income:
Foreign currency translation adjustments(232)197
Comprehensive income (loss) attributable to Ultralife Corporation$2,659$(149)
Net income (loss) per share attributable to Ultralife common stockholders – basic$.18$(.02)
Net income (loss) per share attributable to Ultralife common stockholders – diluted$.18$(.02)
Weighted average shares outstanding – basic16,39616,135
Potential common shares122-
Weighted average shares outstanding - diluted16,51816,135

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands) (Unaudited)

Three-month period ended
March 31, 2024March 31, 2023
OPERATING ACTIVITIES:
Net income (loss)$2,904$(335)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation740762
Amortization of intangible assets228209
Amortization of financing fees1616
Stock-based compensation161139
Deferred income taxes650(390)
Changes in operating assets and liabilities:
Accounts receivable(3,562)3,365
Inventories(1,699)(6,026)
Prepaid expenses and other assets1,102639
Accounts payable and other liabilities(621)256
Net cash used in operating activities(81)(1,365)
INVESTING ACTIVITIES:
Purchases of property, plant and equipment(372)(497)
Net cash used in investing activities(372)(497)
FINANCING ACTIVITIES:
Borrowings on revolving credit facility-2,300
Payments on term loan facility(500)(500)
Proceeds from exercise of stock options685-
Net cash provided by financing activities1851,800
Effect of exchange rate changes on cash89(46)
DECREASE IN CASH(179)(108)
Cash, Beginning of period10,2785,713
Cash, End of period$10,099$5,605

The accompanying notes are an integral part of these consolidated financial statements.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(In Thousands except share amounts) (Unaudited)

Capital · Accumulated
Common Stock · in Excess · Other · Non-
Number of · of Par · Comprehensive · Accumulated · Treasury · Controlling
SharesAmountValueIncome (Loss)DeficitStockInterestTotal
Balance – December 31, 202220,570,710$2,057$187,405$(3,750)$(47,951)$(21,484)$126$116,403
Net loss(346)11(335)
Stock option exercises-
Stock-based compensation – stock options138138
Stock-based compensation – restricted stock11
Foreign currency translation adjustments adjustments197197
Balance – March 31, 202320,570,710$2,057$187,544$(3,553)$(48,297)$(21,484)$137$116,404
Balance – December 31, 202320,783,607$2,078$189,160$(3,660)$(40,754)$(21,492)$95$125,427
Net income2,891132,904
Stock option exercises103,83911674685
Stock-based compensation – stock options156156
Stock-based compensation – restricted stock55
Foreign currency translation adjustments adjustments(232)(232)
Balance – March 31, 202420,887,446$2,089$189,995$(3,892)$(37,863)$(21,492)$108$128,945

ULTRALIFE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands except share and per share amounts)

(Unaudited)

1.BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2023.

The December 31, 2023 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.

Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.

Recently Adopted Accounting Guidance

None.

Recent Accounting Guidance Not Yet Adopted

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

2.DEBT

On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation and wholly owned subsidiary of Ultralife (“SWE”), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE (“CLB”), Ultralife Excell Holding Corp., a Delaware corporation and wholly owned subsidiary of Ultralife (“UEHC”), Ultralife Canada Holding Corp., a Delaware corporation and wholly owned subsidiary of UEHC (“UCHC”), and Excell Battery Corporation USA, a Texas corporation and wholly owned subsidiary of UEHC (“Excell USA”), as borrowers, entered into the Second Amendment Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the “Credit Agreement”). On November 28, 2022, Ultralife, SWE, CLB, UEHC, UCHC, Excell USA, and Excell Battery Canada ULC, a British Columbia unlimited liability corporation and wholly owned subsidiary of UCHC (“Excell Canada”), entered into that certain Third Amendment Agreement with KeyBank, to further amend the Credit Agreement to, among other things, facilitate the joinder of Excell Canada as a guarantor under the Credit Agreement and to replace the LIBOR benchmark thereunder with SOFR (the “Third Amendment Agreement”, and together with the Second Amendment Agreement and the Credit Agreement, the “Amended Credit Agreement”).

The Amended Credit Agreement, among other things, provides for a 5-year, $10,000 senior secured term loan (the “Term Loan Facility”) and extends the term of the $30,000 senior secured revolving credit facility (the “Revolving Credit Facility”, and together with the Term Loan Facility, the “Amended Credit Facilities”) through May 30, 2025. Up to six months prior to May 30, 2025, the Revolving Credit Facility may be increased to $50,000 with the Bank’s concurrence.

As of March 31, 2024, the Company had $5,667 outstanding principal on the Term Loan Facility, $2,000 of which is included in current portion of long-term debt on the balance sheet, and $19,580 outstanding on the Revolving Credit Facility. As of March 31, 2024, total unamortized debt issuance costs of $107, including placement, renewal and legal fees associated with the Amended Credit Agreement, are classified as a reduction of long-term debt on the balance sheet. Debt issuance costs are amortized to interest expense over the term of the Amended Credit Facilities.

The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.

The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2025. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio, as defined in the Amended Credit Agreement, of equal to or less than 3.5 to 1.0 for the fiscal quarters ending December 31, 2022 and March 31, 2023, and equal to or less than 3.0 to 1.0 for the fiscal quarters ending June 30, 2023 and thereafter. The Company was in full compliance with its covenants under the Amended Credit Agreement as of March 31, 2024.

Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.

Upon the effectiveness of the Third Amendment Agreement, interest accrues on outstanding indebtedness under the Amended Credit Facilities at the Daily Simple SOFR Rate, plus an index spread adjustment of 0.10%, plus the applicable margin. The applicable margin ranges from 185 to 215 basis points and is determined based on the Company’s senior leverage ratio.

The Company must pay a fee of 0.15% to 0.25% based on the average daily unused availability under the Revolving Credit Facility.

Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

3.EARNINGS PER SHARE

Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife Corporation by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities, if any, and is calculated using the treasury stock method.

For the three-month period ended March 31, 2024, there were 539,358 outstanding stock options and 5,229 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 122,515 potential common shares included in the calculation of diluted EPS. There were 524,502 outstanding stock options for the three-month period ended March 31, 2024 not included in EPS as the effect would be anti-dilutive.

For the comparable three-month period ended March 31, 2023, there wereno outstanding awards included in the calculation of diluted weighted average shares outstanding andno potential common shares included in the calculation of diluted EPS, as no securities were dilutive. There were 1,420,611 outstanding stock options and 2,500 unvested restricted stock awards not included in the calculation of diluted EPS for the three-month period ended March 31, 2023, as the effect would be antidilutive.

4.SUPPLEMENTAL BALANCE SHEET INFORMATION

Fair Value Measurements and Disclosures

The fair value of financial instruments approximated their carrying values at March 31, 2024 and December 31, 2023. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments.

Cash

The composition of the Company’s cash was as follows:

March 31,December 31,
20242023
Cash$10,099$10,196
Restricted cash-82
Total$10,099$10,278

As December 31, 2023, restricted cash of $82 represented euro-denominated deposits withheld by the Dutch tax authorities and third-party VAT representatives in connection with a previously utilized logistics arrangement in the Netherlands. During the quarter ended March 31, 2024, the deposits were returned to the Company and no longer restricted. As of March 31, 2024, there was no cash classified as restricted cash. Restricted cash as of December 31, 2023 is included as a component of the cash balance for purposes of the consolidated statements of cash flows.

Inventories, Net

Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

March 31,December 31,
20242023
Raw materials$30,168$29,098
Work in process3,5933,187
Finished goods10,0609,930
Total$43,821$42,215

Property, Plant and Equipment, Net

Major classes of property, plant and equipment consisted of the following:

March 31,December 31,
20242023
Land$1,273$1,273
Buildings and leasehold improvements16,00715,998
Machinery and equipment57,42757,584
Furniture and fixtures2,8182,845
Computer hardware and software7,7707,868
Construction in process1,6952,033
86,99087,601
Less: Accumulated depreciation(66,320)(66,484)
Property, plant and equipment, net$20,670$21,117

Depreciation expense for property, plant and equipment was $740 and $762 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively.

Goodwill

The following table summarizes the goodwill activity by segment for the three-month period ended March 31, 2024.

Battery & Energy · Communications
ProductsSystemsTotal
Balance – December 31, 2023$26,078$11,493$37,571
Effect of foreign currency translation(72)-(72)
Balance – March 31, 2024$26,006$11,493$37,499

Other Intangible Assets, Net

The composition of other intangible assets was:

Accumulated
CostAmortizationNet
Customer relationships$13,072$6,796$6,276
Patents and technology5,5975,344253
Trade names4,6456733,972
Trademarks3,400-3,400
Other1,500534966
Total other intangible assets$28,214$13,347$14,867
Accumulated
CostAmortizationNet
Customer relationships$13,092$6,656$6,436
Patents and technology5,6065,322284
Trade names4,6476474,000
Trademarks3,402-3,402
Other1,500515985
Total other intangible assets$28,247$13,140$15,107

The change in the cost of total intangible assets from December 31, 2023 to March 31, 2024 is the effect of foreign currency translations.

Amortization expense for intangible assets was $228 and $209 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively. Amortization included in selling, general and administrative expenses was $203 and $185 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively. Amortization included in research and development expenses was $25 and $24 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively.

5.STOCK-BASED COMPENSATION

We recorded non-cash stock compensation expense in each period as follows:

Three-month period ended
March 31,March 31,
20242023
Stock options$156$138
Restricted stock grants51
Total$161$139

We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of March 31, 2024, there was $699 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 1.3 years.

The following table summarizes stock option activity for the three-month period ended March 31, 2024:

Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (years)Aggregate Intrinsic Value
Outstanding at January 1, 20241,250,595$7.10
Granted3,4606.84
Exercised(103,839)6.60
Forfeited or expired(86,356)$8.96
Outstanding at March 31, 20241,063,860$7.004.22$2,258
Vested and expected to vest at March 31, 2024964,552$7.074.06$1,987
Exercisable at March 31, 2024604,537$7.502.92$1,018

Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended March 31, 2024 and March 31, 2023 was $685 and $0, respectively.

Restricted stock awards vest in equal annual installments over three(3) years. Unrecognized compensation cost related to unvested restricted shares at March 31, 2024 and March 31, 2023, respectively, was $31 and $2.

6.INCOME TAXES

Our effective tax rate for the three-month periods ended March 31, 2024 and March 31, 2023 was 19.5% and 28.4%, respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results.

As of December 31, 2023, we have domestic net operating loss (“NOL”) carryforwards of $27,200, which expire 2031 through 2035, and domestic tax credits of $2,900, which expire 2028 through 2043, available to reduce future taxable income. As of March 31, 2024, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.

As of March 31, 2024, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $9,800, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

As of March 31, 2024, we havenot recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.

As of March 31, 2024, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

There wereno unrecognized tax benefits related to uncertain tax positions at March 31, 2024 and December 31, 2023.

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2020 thru 2022 remain subject to IRS examination. Our U.S. tax matters for 2001-2002,2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2013 thru 2022 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2013 thru 2022 remain subject to examination by the respective foreign tax jurisdiction authorities.

7.OPERATING LEASES

The Company has operating leases predominantly for operating facilities. As of March 31, 2024, the remaining lease terms on our operating leases range from approximately less than one (1) year to eight (8) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

The components of lease expense for the current and prior-year comparative periods were as follows:

Three-month period ended March 31,
20242023
Operating lease cost$262$241
Variable lease cost2828
Total lease cost$290$269

Supplemental cash flow information related to leases was as follows:

Three-month period ended March 31,
2024 · 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$265$226
Right-of-use assets obtained in exchange for lease liabilities:$-$-

Supplemental consolidated balance sheet information related to leases was as follows:

Balance sheet classification · March 31, 2024 · December 31, 2023
Assets:
Operating lease right-of-use assetOther noncurrent assets$3,177$3,589
Liabilities:
Current operating lease liabilityAccrued expenses and other current liabilities$780$894
Operating lease liability, net of current portionOther noncurrent liabilities2,3502,644
Total operating lease liability$3,130$3,538
Weighted-average remaining lease term (years)5.25.3
Weighted-average discount rate6.3%4.5%

Future minimum lease payments as of March 31, 2024 are as follows:

Maturity of operating lease liabilities
2024$620
2025691
2026618
2027639
2028642
Thereafter458
Total lease payments3,668
Less: Imputed interest(538)
Present value of remaining lease payments$3,130
8.COMMITMENTS AND CONTINGENCIES

Purchase Commitments

As of March 31, 2024, we have made commitments to purchase approximately $330 of production machinery and equipment.

Product Warranties

We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first three months of 2024 and 2023 were as follows:

Three-month period ended March 31,
20242023
Accrued warranty obligations – beginning$547$323
Accruals for warranties issued14184
Settlements made(49)(21)
Accrued warranty obligations – ending$639$386

Contingencies and Legal Matters

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.

9.REVENUE RECOGNITION

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet. For the quarter ended March 31, 2024, revenue recognized on extended warranties was $72.

As of March 31, 2024, there was deferred revenue on extended warranty contracts of $1,335, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $1,048 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

As of December 31, 2023, there was deferred revenue on extended warranty contracts of $1,407, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $1,120 expected to be recognized as revenue evenly over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

As of March 31, 2024 and December 31, 2023, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

10.BUSINESS SEGMENT INFORMATION

We report our results intwo operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance.

Three-month period ended March 31, 2024:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$34,989$6,938$-$41,927
Segment contribution8,9862,484(7,407)4,063
Other expense(456)(456)
Tax provision(703)(703)
Non-controlling interest(13)(13)
Net income attributable to Ultralife Corporation$2,891

Three-month period ended March 31, 2023:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$28,470$3,446$-$31,916
Segment contribution6,512924(7,410)26
Other expense(494)(494)
Tax benefit133133
Non-controlling interest(11)(11)
Net loss attributable to Ultralife Corporation$(346)

The following tables disaggregate our business segment revenues by major source and geography.

Commercial and Government/Defense Revenue Information:

Three-month period ended March 31, 2024:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$34,989$24,140$10,849
Communications Systems6,938-6,938
Total$41,927$24,140$17,787
58%42%

Three-month period ended March 31, 2023:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$28,470$22,219$6,251
Communications Systems3,446-3,446
Total$31,916$22,219$9,697
70%30%

U.S. and Non-U.S. Revenue Information 1:

Three-month period ended March 31, 2024:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$34,989$19,603$15,386
Communications Systems6,9384,8582,080
Total$41,927$24,461$17,466
58%42%

Three-month period ended March 31, 2023:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$28,470$13,768$14,702
Communications Systems3,4462,877569
Total$31,916$16,645$15,271
52%48%

1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.